Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2016 Sep 9:6:33104.
doi: 10.1038/srep33104.

Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C

Affiliations

VSports注册入口 - Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C

Kuo-Tung Tang et al. Sci Rep. .

Abstract

A few studies have shown that methotrexate (MTX) use exacerbates liver fibrosis and even leads to liver cirrhosis in rheumatoid arthritis (RA) patients, although the risk is low compared to psoriatics. We therefore conducted a population-based cohort study to investigate the impact of long-term MTX use on the risk of chronic hepatitis C (CHC)-related cirrhosis among RA patients VSports手机版. We analyzed data from the National Health Insurance Research Database in Taiwan and identified 450 incident cases of RA among CHC patients (255 MTX users and 195 MTX non-users) from January 1, 1998 to December 31, 2007. After a median follow-up of more than 5 years since the diagnosis of CHC, a total of 55 (12%) patients developed liver cirrhosis. We did not find an increased risk of liver cirrhosis among CHC patients with long-term MTX use for RA. Furthermore, there was no occurrence of liver cirrhosis among the 43 MTX users with a cumulative dose ≧3 grams after 108 months of treatment. In conclusion, our data showed that long-term MTX use is not associated with an increased risk for liver cirrhosis among RA patients with CHC. However, these results should be interpreted with caution due to potential bias in the cohort. .

PubMed Disclaimer

Figures

Figure 1
Figure 1. The flow chart of identification of RA patients with CHC.
CHC, chronic hepatitis C; MTX, methotrexate; NHIRD, the National Health Insurance Research Database; RA, rheumatoid arthritis.
Figure 2
Figure 2. Probability of liver cirrhosis-free survival among MTX users with different cumulative doses and MTX non-users (p < 0.001, log-rank test).
MTX, methotrexate.

V体育平台登录 - References

    1. Aithal G. P. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 7, 139–150 (2011). - PubMed
    1. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 42, 531–534 (2000). - PubMed
    1. Whiting-O’Keefe Q. E., Fye K. H. & Sack K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90, 711–716 (1991). - PubMed
    1. Tang K. T., Hung W. T., Chen Y. H., Lin C. H. & Chen D. Y. Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. Sci Rep 6, 22387 (2016). - PMC - PubMed
    1. Heidelbaugh J. J. & Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician 74, 767–776 (2006). - PubMed

"V体育官网入口" Publication types

MeSH terms

"VSports app下载" LinkOut - more resources